Diabetes
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Khandoudi, N.
Right arrow Articles by Bril, A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Khandoudi, N.
Right arrow Articles by Bril, A.
Social Bookmarking
Add to CiteULike   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?
Diabetes 51:1507-1514, 2002
© 2002 by the American Diabetes Association, Inc.

Rosiglitazone, a Peroxisome Proliferator-Activated Receptor-{gamma}, Inhibits the Jun NH2-Terminal Kinase/Activating Protein 1 Pathway and Protects the Heart From Ischemia/Reperfusion Injury

Nassirah Khandoudi1, Philippe Delerive2, Isabelle Berrebi-Bertrand1, Robin E. Buckingham1, Bart Staels2, and Antoine Bril1

1 Cardiovascular and Urogenital Diseases Center of Excellence for Drug Discovery, GlaxoSmithKline Pharmaceuticals, King of Prussia, Pennsylvania
2 Unit 545 Institut National de la Santé et de la Recherche Médicale (INSERM), Département d’Athéroslérose, Institut Pasteur de Lille, and Faculté de Pharmacie, Université de Lille II, Lille, France

This study was conducted to evaluate whether treatment of normal and diabetic rat hearts with rosiglitazone, a high-affinity ligand of the peroxisome proliferator-activated receptor-{gamma} (PPAR-{gamma}) used for the treatment of type 2 diabetes, improves postischemic functional recovery. The effects of acute rosiglitazone administration were investigated using working hearts isolated from normal rat or rats diabetic for 4 weeks after streptozotocin (STZ) injection. Hearts were subjected to 30 min of normothermic, zero-flow ischemia followed by 30-min reperfusion. Rosiglitazone (1 µmol/l) administered before ischemia had no effect on cardiac function during baseline perfusion, but it significantly improved aortic flow during reperfusion in both normal and diabetic hearts. In a chronic protocol in which rosiglitazone was given by daily gavage (10 µmol/kg body wt) immediately after STZ injection, rosiglitazone also prevented postischemic injury and significantly improved functional recovery. Using Western immunoblotting, it was demonstrated that the acute cardioprotective effect of rosiglitazone is associated with an inhibition of Jun NH2-terminal kinase phosphorylation in both normal and diabetic rat hearts. Furthermore, rosiglitazone also inhibited activating protein-1 DNA-binding activity. These data, demonstrating that rosiglitazone limits postischemic injury in isolated hearts, suggest an important function for PPAR-{gamma} in the heart.


Add to CiteULike CiteULike   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?


This article has been cited by other articles:


Home page
 J Am Coll CardiolHome page
A. J. Gilde, J.-C. Fruchart, and B. Staels
Peroxisome Proliferator-Activated Receptors at the Crossroads of Obesity, Diabetes, and Cardiovascular Disease
J. Am. Coll. Cardiol., October 27, 2006; 48(9_Suppl_A): A24 - A32.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Physiol. Heart Circ. Physiol.Home page
N. Sambandam, D. Morabito, C. Wagg, B. N. Finck, D. P. Kelly, and G. D. Lopaschuk
Chronic activation of PPAR{alpha} is detrimental to cardiac recovery after ischemia
Am J Physiol Heart Circ Physiol, January 1, 2006; 290(1): H87 - H95.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Physiol. Heart Circ. Physiol.Home page
Y. Xu, M. Gen, L. Lu, J. Fox, S. O. Weiss, R. D. Brown, D. Perlov, H. Ahmad, P. Zhu, C. Greyson, et al.
PPAR-{gamma} activation fails to provide myocardial protection in ischemia and reperfusion in pigs
Am J Physiol Heart Circ Physiol, March 1, 2005; 288(3): H1314 - H1323.
[Abstract] [Full Text] [PDF]

Home page
 DiabetesHome page
T.-L. Yue, W. Bao, J.-L. Gu, J. Cui, L. Tao, X.-L. Ma, E. H. Ohlstein, and B. M. Jucker
Rosiglitazone Treatment in Zucker Diabetic Fatty Rats Is Associated With Ameliorated Cardiac Insulin Resistance and Protection From Ischemia/Reperfusion-Induced Myocardial Injury
Diabetes, February 1, 2005; 54(2): 554 - 562.
[Abstract] [Full Text] [PDF]

Home page
 J. Pharmacol. Exp. Ther.Home page
C.-Y. Xiao, M. Chen, Z. Zsengeller, and C. Szabo
Poly(ADP-Ribose) Polymerase Contributes to the Development of Myocardial Infarction in Diabetic Rats and Regulates the Nuclear Translocation of Apoptosis-Inducing Factor
J. Pharmacol. Exp. Ther., August 1, 2004; 310(2): 498 - 504.
[Abstract] [Full Text] [PDF]

Home page
 Circ. Res.Home page
N. Marx, H. Duez, J.-C. Fruchart, and B. Staels
Peroxisome Proliferator-Activated Receptors and Atherogenesis: Regulators of Gene Expression in Vascular Cells
Circ. Res., May 14, 2004; 94(9): 1168 - 1178.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Physiol. Endocrinol. Metab.Home page
A. N. Carley, L. M. Semeniuk, Y. Shimoni, E. Aasum, T. S. Larsen, J. P. Berger, and D. L. Severson
Treatment of type 2 diabetic db/db mice with a novel PPAR{gamma} agonist improves cardiac metabolism but not contractile function
Am J Physiol Endocrinol Metab, March 1, 2004; 286(3): E449 - E455.
[Abstract] [Full Text]

Home page
 Arterioscler. Thromb. Vasc. Bio.Home page
J. L. Mehta, B. Hu, J. Chen, and D. Li
Pioglitazone Inhibits LOX-1 Expression in Human Coronary Artery Endothelial Cells by Reducing Intracellular Superoxide Radical Generation
Arterioscler. Thromb. Vasc. Biol., December 1, 2003; 23(12): 2203 - 2208.
[Abstract] [Full Text] [PDF]

Home page
 DiabetesHome page
Y. Xu, L. Lu, C. Greyson, J. Lee, M. Gen, K. Kinugawa, C. S. Long, and G. G. Schwartz
Deleterious Effects of Acute Treatment With a Peroxisome Proliferator-Activated Receptor-{gamma} Activator in Myocardial Ischemia and Reperfusion in Pigs
Diabetes, May 1, 2003; 52(5): 1187 - 1194.
[Abstract] [Full Text] [PDF]

Home page
 CirculationHome page
C.-H. Wang, R. D. Weisel, P. P. Liu, P. W.M. Fedak, and S. Verma
Glitazones and Heart Failure: Critical Appraisal for the Clinician
Circulation, March 18, 2003; 107(10): 1350 - 1354.
[Full Text] [PDF]

Home page
 SEMIN CARDIOTHORAC VASC ANESTHHome page
C. J. Tack
Insulin Resistance and Acute Cardiovascular Complications
Seminars in Cardiothoracic and Vascular Anesthesia, March 1, 2003; 7(1): 85 - 90.
[PDF]

Home page
 J. Biol. Chem.Home page
C. Dello Russo, V. Gavrilyuk, G. Weinberg, A. Almeida, J. P. Bolanos, J. Palmer, D. Pelligrino, E. Galea, and D. L. Feinstein
Peroxisome Proliferator-activated Receptor gamma Thiazolidinedione Agonists Increase Glucose Metabolism in Astrocytes
J. Biol. Chem., February 14, 2003; 278(8): 5828 - 5836.
[Abstract] [Full Text] [PDF]

Home page
 DiabetesHome page
E. Aasum, A. D. Hafstad, D. L. Severson, and T. S. Larsen
Age-Dependent Changes in Metabolism, Contractile Function, and Ischemic Sensitivity in Hearts From db/db Mice
Diabetes, February 1, 2003; 52(2): 434 - 441.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
X. Zhang, P. Shan, L. E. Otterbein, J. Alam, R. A. Flavell, R. J. Davis, A. M. K. Choi, and P. J. Lee
Carbon Monoxide Inhibition of Apoptosis during Ischemia-Reperfusion Lung Injury Is Dependent on the p38 Mitogen-activated Protein Kinase Pathway and Involves Caspase 3
J. Biol. Chem., January 3, 2003; 278(2): 1248 - 1258.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Diabetes Diabetes Care Clinical Diabetes Diabetes Spectrum
Copyright © 2002 by the American Diabetes Association.